Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

William Plunkett

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Antineoplastic Combined Chemotherapy Protocols

Anatomy

Cultured Tumor Cells

Concepts & Ideas

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
73
Gandhi, Varsha
63
Keating, Michael
38
Huang, Peng
25
Kantarjian, Hagop
24
O'Brien, Susan
23
Estey, Elihu
17
Du, Min
15
Robertson, LE
12
Sampath, Deepa
11
Beran, Miloslav
11
Kantarjian, Hagop
10
Keating, Michael
9
Koller, Charles
9
Hittelman, Walter
9
Faderl, Stefan

Sign-in to see all Coauthors

Publications

TOP 3
Pounds Stan; Cheng Cheng; Cao Xueyuan; Crews Kristine R; Plunkett William; Gandhi Varsha; Rubnitz Jeffrey; Ribeiro Raul C; Downing James R; Lamba Jatinder
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables.
Chen Rong; Wierda William G; Chubb Sherri; Hawtin Rachael E; Fox Judith A; Keating Michael J; Gandhi Varsha; Plunkett William
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Sampath Deepa; Calin George A; Puduvalli Vinay K; Gopisetty Gopal; Taccioli Cristian; Liu Chang-Gong; Ewald Brett; Liu Chaomei; Keating Michael J; Plunkett William
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of William Plunkett (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Pounds Stan; Cheng Cheng; Cao Xueyuan; Crews Kristine R; Plunkett William; Gandhi Varsha; Rubnitz Jeffrey; Ribeiro Raul C; Downing James R; Lamba Jatinder
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables.
Bioinformatics (Oxford, England) 2009;25(16):2013-9.
2009: Chen Rong; Wierda William G; Chubb Sherri; Hawtin Rachael E; Fox Judith A; Keating Michael J; Gandhi Varsha; Plunkett William
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Blood 2009;113(19):4637-45.
2009: Sampath Deepa; Calin George A; Puduvalli Vinay K; Gopisetty Gopal; Taccioli Cristian; Liu Chang-Gong; Ewald Brett; Liu Chaomei; Keating Michael J; Plunkett William
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.
Blood 2009;113(16):3744-53.
2008: Borthakur Gautam; Kantarjian Hagop; Wang Xuemei; Plunkett William K; Gandhi Varsha V; Faderl Stefan; Garcia-Manero Guillermo; Ravandi Farhad; Pierce Sherry; Estey Elihu H
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Cancer 2008;113(11):3181-5.
2008: Ewald B; Sampath D; Plunkett W
Nucleoside analogs: molecular mechanisms signaling cell death.
Oncogene 2008;27(50):6522-37.
2008: Ewald Brett; Sampath Deepa; Plunkett William
ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.
Cancer research 2008;68(19):7947-55.
2008: Chen Lisa S; Plunkett William; Gandhi Varsha
Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.
Leukemia research 2008;32(10):1573-81.
2008: Trachootham Dunyaporn; Zhang Hui; Zhang Wan; Feng Li; Du Min; Zhou Yan; Chen Zhao; Pelicano Helene; Plunkett William; Wierda William G; Keating Michael J; Huang Peng
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
Blood 2008;112(5):1912-22.
2008: Wang Yaqing; Liu Xiaojun; Matsuda Akira; Plunkett William
Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.
Cancer research 2008;68(10):3881-9.
2008: Gandhi Varsha; Tam Constantine; O'Brien Susan; Jewell Roxanne C; Rodriguez Carlos O; Lerner Susan; Plunkett William; Keating Michael J
Phase I trial of nelarabine in indolent leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1098-105.
2008: Liu Xiaojun; Matsuda Akira; Plunkett William
Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.
Molecular cancer therapeutics 2008;7(1):133-42.
2008: Tsimberidou Apostolia M; Wierda William G; Plunkett William; Kurzrock Razelle; O'Brien Susan; Wen Sijin; Ferrajoli Alessandra; Ravandi-Kashani Farhad; Garcia-Manero Guillermo; Estrov Zeev; Kipps Thomas J; Brown Jennifer R; Fiorentino Albert; Lerner Susan; Kantarjian Hagop M; Keating Michael J
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):196-203.
2007: Tili Esmerina; Michaille Jean-Jacques; Gandhi Varsha; Plunkett William; Sampath Deepa; Calin George Adrian
miRNAs and their potential for use against cancer and other diseases.
Future oncology (London, England) 2007;3(5):521-37.
2007: Guo Lei; Liu Xiaojun; Nishikawa Kiyohiro; Plunkett William
Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Molecular cancer therapeutics 2007;6(5):1501-8.
2007: Ewald Brett; Sampath Deepa; Plunkett William
H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
Molecular cancer therapeutics 2007;6(4):1239-48.
2006: Pelicano Hélène; Xu Rui-Hua; Du Min; Feng Li; Sasaki Ryohei; Carew Jennifer S; Hu Yumin; Ramdas Latha; Hu Limei; Keating Michael J; Zhang Wei; Plunkett William; Huang Peng
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism.
The Journal of cell biology 2006;175(6):913-23.
2006: Moufarij Mazin A; Sampath Deepa; Keating Michael J; Plunkett William
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Blood 2006;108(13):4187-93.
2006: Chen Rong; Gandhi Varsha; Plunkett William
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Cancer research 2006;66(22):10959-66.
2006: Gandhi Varsha; Plunkett William
Clofarabine and nelarabine: two new purine nucleoside analogs.
Current opinion in oncology 2006;18(6):584-90.
2006: Kojima Kensuke; Konopleva Marina; McQueen Teresa; O'Brien Susan; Plunkett William; Andreeff Michael
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Blood 2006;108(3):993-1000.
2006: Gandhi Varsha; Plunkett William; Bonate Peter L; Du Min; Nowak Billie; Lerner Susan; Keating Michael J
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):4011-7.
2006: Pelicano H; Carew J S; McQueen T J; Andreeff M; Plunkett W; Keating M J; Huang P
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(4):610-9.
2006: Kantarjian Hagop; Beran Miloslav; Cortes Jorge; O'Brien Susan; Giles Francis; Pierce Sherry; Shan Jianqin; Plunkett William; Keating Michael; Estey Elihu
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006;106(5):1099-109.
2006: Sampath Deepa; Cortes Jorge; Estrov Zeev; Du Min; Shi Zheng; Andreeff Michael; Gandhi Varsha; Plunkett William
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Blood 2006;107(6):2517-24.
2005: Gandhi Varsha; Kilpatrick John M; Plunkett William; Ayres Mary; Harman Leigh; Du Min; Bantia Shanta; Davisson Jan; Wierda William G; Faderl Stefan; Kantarjian Hagop; Thomas Deborah
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Blood 2005;106(13):4253-60.
2005: Chen Rong; Keating Michael J; Gandhi Varsha; Plunkett William
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Blood 2005;106(7):2513-9.
2005: Liu Xiaojun; Guo Ying; Li Yexiong; Jiang Yingjun; Chubb Sherri; Azuma Atsushi; Huang Peng; Matsuda Akira; Hittelman Walter; Plunkett William
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Cancer research 2005;65(15):6874-81.
2005: Jabbour Elias; Verstovsek Srdan; Giles Francis; Gandhi Varsha; Cortes Jorge; O'Brien Susan; Plunkett William; Garcia-Manero Guillermo; Jackson C Ellen; Kantarjian Hagop; Andreeff Michael
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Cancer 2005;104(3):541-6.
2005: Keating Michael J; O'Brien Susan; Albitar Maher; Lerner Susan; Plunkett William; Giles Francis; Andreeff Michael; Cortes Jorge; Faderl Stefan; Thomas Deborah; Koller Charles; Wierda William; Detry Michelle A; Lynn Alice; Kantarjian Hagop
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: Xiong Henry Q; Plunkett William; Wolff Robert; Du Min; Lenzi Renato; Abbruzzese James L
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Cancer chemotherapy and pharmacology 2005;55(6):559-64.
2005: Faderl Stefan; Gandhi Varsha; Keating Michael J; Jeha Sima; Plunkett William; Kantarjian Hagop M
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Cancer 2005;103(10):1985-95.
2005: Faderl Stefan; Gandhi Varsha; O'Brien Susan; Bonate Peter; Cortes Jorge; Estey Elihu; Beran Miloslav; Wierda William; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; Giles Francis J; Du Min; Kwari Monica; Keating Michael; Plunkett William; Kantarjian Hagop
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005;105(3):940-7.
2004: Bonate Peter L; Craig Adam; Gaynon Paul; Gandhi Varsha; Jeha Sima; Kadota Richard; Lam Gilbert N; Plunkett William; Razzouk Bassem; Rytting Michael; Steinherz Peter; Weitman Steve
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.
Journal of clinical pharmacology 2004;44(11):1309-22.
2004: Jeha Sima; Gandhi Varsha; Chan Ka Wah; McDonald Lisa; Ramirez Irma; Madden Renee; Rytting Michael; Brandt Mark; Keating Michael; Plunkett William; Kantarjian Hagop
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
Blood 2004;103(3):784-9.
2003: Gandhi Varsha; Kantarjian Hagop; Faderl Stefan; Bonate Peter; Du Min; Ayres Mary; Rios Mary Beth; Keating Michael J; Plunkett William
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6335-42.
2003: Sampath Deepa; Rao V Ashutosh; Plunkett William
Mechanisms of apoptosis induction by nucleoside analogs.
Oncogene 2003;22(56):9063-74.
2003: Giles Francis J; Fracasso Paula M; Kantarjian Hagop M; Cortes Jorge E; Brown Randy A; Verstovsek Srdan; Alvarado Yesid; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Wright Lisa P; Samson Tom; Cahill Ann; Lambert Paula; Plunkett William; Sznol Mario; DiPersio John F; Gandhi Varsha
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia research 2003;27(12):1077-83.
2003: Yang Li-Ying; Jiang Hong; Rangel Kelly M; Plunkett William
Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01).
Oncology reports 2003;10(5):1489-95.
2003: Pelicano Hélène; Feng Li; Zhou Yan; Carew Jennifer S; Hileman Elizabeth O; Plunkett William; Keating Michael J; Huang Peng
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism.
The Journal of biological chemistry 2003;278(39):37832-9.
2003: Rao V Ashutosh; Plunkett William
Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):3204-12.
2003: Zhou Yan; Hileman Elizabeth O; Plunkett William; Keating Michael J; Huang Peng
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents.
Blood 2003;101(10):4098-104.
2003: Kantarjian Hagop M; Gandhi Varsha; Kozuch Peter; Faderl Stefan; Giles Francis; Cortes Jorge; O'Brien Susan; Ibrahim Nuhad; Khuri Fadlo; Du Min; Rios Mary Beth; Jeha Sima; McLaughlin Peter; Plunkett William; Keating Michael
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1167-73.
2002: Keating M J; O'Brien S; Kontoyiannis D; Plunkett W; Koller C; Beran M; Lerner S; Kantarjian H
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
Leukemia & lymphoma 2002;43(9):1755-62.
2002: Sampath Deepa; Shi Zheng; Plunkett William
Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.
Molecular pharmacology 2002;62(3):680-8.
2002: Yamauchi Takahiro; Keating Michael J; Plunkett William
UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes.
Molecular cancer therapeutics 2002;1(4):287-94.
2002: Gandhi Varsha; Plunkett William; Du Min; Ayres Mary; Estey Elihu H
Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):665-73.
2002: Zhou Yan; Achanta Geetha; Pelicano Helene; Gandhi Varsha; Plunkett William; Huang Peng
Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response.
Molecular pharmacology 2002;61(1):222-9.
2002: Faderl Stefan; Gandhi Varsha; Kantarjian Hagop; Plunkett William
New nucleoside analogues in clinical development.
Cancer chemotherapy and biological response modifiers 2002;20():37-58.
2002: Gandhi Varsha; Plunkett William
Cellular and clinical pharmacology of fludarabine.
Clinical pharmacokinetics 2002;41(2):93-103.
2001: Achanta G; Pelicano H; Feng L; Plunkett W; Huang P
Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage.
Cancer research 2001;61(24):8723-9.
2001: Yamauchi T; Nowak B J; Keating M J; Plunkett W
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3580-9.
2001: Sampath D; Plunkett W
Design of new anticancer therapies targeting cell cycle checkpoint pathways.
Current opinion in oncology 2001;13(6):484-90.
2001: Patel S R; Gandhi V; Jenkins J; Papadopolous N; Burgess M A; Plager C; Plunkett W; Benjamin R S
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(15):3483-9.
2001: Millikan R E; Plunkett W K; Smith T L; Williams D L; Logothetis C J
Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin.
Cancer 2001;92(1):194-9.
2001: Azuma A; Huang P; Matsuda A; Plunkett W
Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC).
Biochemical pharmacology 2001;61(12):1497-507.
2001: Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez C O; Ramakrishna P; Rosner G L; Hodge J P; O'Brien S; Keating M J
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2142-52.
2001: Azuma A; Huang P; Matsuda A; Plunkett W
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
Molecular pharmacology 2001;59(4):725-31.
2001: Shi Z; Azuma A; Sampath D; Li Y X; Huang P; Plunkett W
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.
Cancer research 2001;61(3):1065-72.
2001: Plunkett W; Gandhi V
Purine and pyrimidine nucleoside analogs.
Cancer chemotherapy and biological response modifiers 2001;19():21-45.
2000: Sampath D; Plunkett W
The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
Cancer research 2000;60(22):6408-15.
2000: Huang P; Feng L; Oldham E A; Keating M J; Plunkett W
Superoxide dismutase as a target for the selective killing of cancer cells.
Nature 2000;407(6802):390-5.
2000: Rodriguez C O; Plunkett W; Paff M T; Du M; Nowak B; Ramakrishna P; Keating M J; Gandhi V
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):421-30.
2000: Huang P; Sandoval A; Van Den Neste E; Keating M J; Plunkett W
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(8):1405-13.
2000: Feng L; Achanta G; Pelicano H; Zhang W; Plunkett W; Huang P
Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage.
International journal of molecular medicine 2000;5(6):597-604.
2000: Yang L Y; Li L; Jiang H; Shen Y; Plunkett W
Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):773-81.
2000: Kisor D F; Plunkett W; Kurtzberg J; Mitchell B; Hodge J P; Ernst T; Keating M J; Gandhi V
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):995-1003.
2000: Esteva F J; Soh L T; Holmes F A; Plunkett W; Meyers C A; Forman A D; Hortobagyi G N
Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
Cancer chemotherapy and pharmacology 2000;46(5):382-6.
1999: Giles F J; O'Brien S M; Santini V; Gandhi V; Plunkett W; Seymour J F; Robertson L E; Kantarjian H M; Keating M J
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Leukemia & lymphoma 1999;36(1-2):57-65.
1999: Aguayo A; Cortes J E; Kantarjian H M; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating M J
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Cancer 1999;85(1):58-64.
1999: Milas L; Fujii T; Hunter N; Elshaikh M; Mason K; Plunkett W; Ang K K; Hittelman W
Enhancement of tumor radioresponse in vivo by gemcitabine.
Cancer research 1999;59(1):107-14.
1998: Gandhi V; Plunkett W; Rodriguez C O; Nowak B J; Du M; Ayres M; Kisor D F; Mitchell B S; Kurtzberg J; Keating M J
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3607-15.
1998: Gandhi V; Plunkett W; Kantarjian H; Talpaz M; Robertson L E; O'Brien S
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2321-31.
1998: Consoli U; El-Tounsi I; Sandoval A; Snell V; Kleine H D; Brown W; Robinson J R; DiRaimondo F; Plunkett W; Andreeff M
Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
Blood 1998;91(5):1742-8.
1997: Li L; Keating M J; Plunkett W; Yang L Y
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Molecular pharmacology 1997;52(5):798-806.
1997: Gandhi V; Estey E; Du M; Keating M J; Plunkett W
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1539-45.
1997: Gandhi V; Huang P; Chapman A J; Chen F; Plunkett W
Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(8):1347-55.
1997: Huang P; Ballal K; Plunkett W
Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis.
Cancer research 1997;57(16):3407-14.
1997: Iwasaki H; Huang P; Keating M J; Plunkett W
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Blood 1997;90(1):270-8.
1997: Li L; Liu X; Glassman A B; Keating M J; Stros M; Plunkett W; Yang L Y
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro.
Cancer research 1997;57(8):1487-94.
1996: Keating M J; O'Brien S; McLaughlin P; Dimopoulos M; Gandhi V; Plunkett W; Lerner S; Kantarjian H; Estey E
Clinical experience with fludarabine in hemato-oncology.
Hematology and cell therapy 1996;38 Suppl 2():S83-91.
1996: Plunkett W; Gandhi V
Pharmacology of purine nucleoside analogues.
Hematology and cell therapy 1996;38 Suppl 2():S67-74.
1996: Grégoire V; Hunter N R; Brock W A; Hittelman W N; Plunkett W; Milas L
Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine.
Radiation research 1996;146(5):548-53.
1996: Sandoval A; Consoli U; Plunkett W
Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1731-41.
1996: Plunkett W; Begleiter A; Liliemark J O; Reed J C
Why do drugs work in CLL?
Leukemia & lymphoma 1996;22 Suppl 2():1-11.
1996: Plunkett W; Huang P; Searcy C E; Gandhi V
Gemcitabine: preclinical pharmacology and mechanisms of action.
Seminars in oncology 1996;23(5 Suppl 10):3-15.
1996: Kornblau S M; Gandhi V; Andreeff H M; Beran M; Kantarjian H M; Koller C A; O'Brien S; Plunkett W; Estey E
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(10):1563-9.
1996: Gandhi V; Legha J; Chen F; Hertel L W; Plunkett W
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.
Cancer research 1996;56(19):4453-9.
1996: Kamiya K; Huang P; Plunkett W
Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA.
The Journal of biological chemistry 1996;271(32):19428-35.
1996: Xie K C; Plunkett W
Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine.
Cancer research 1996;56(13):3030-7.
1996: Gandhi V; Estey E H; Keating M J; Plunkett W
Intracellular pharmacodynamics in leukemia therapy.
[Rinsho ketsueki] The Japanese journal of clinical hematology 1996;37(5):369-79.
1996: Seymour J F; Huang P; Plunkett W; Gandhi V
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(4):653-8.
1996: McConkey D J; Chandra J; Wright S; Plunkett W; McDonnell T J; Reed J C; Keating M
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(7):2624-30.
1996: Robertson L E; Plunkett W; McConnell K; Keating M J; McDonnell T J
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(3):456-9.
1996: Gandhi V; Estey E; Keating M J; Chucrallah A; Plunkett W
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Blood 1996;87(1):256-64.
1996: Loughlin S; Gandhi V; Plunkett W; Zwelling L A
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
Cancer chemotherapy and pharmacology 1996;38(3):261-8.
1996: Robertson L E; Denny A W; Huh Y O; Plunkett W; Keating M J; Nelson J A
Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
Cancer chemotherapy and pharmacology 1996;37(5):445-50.
1995: Benvenuto J A; Hittelman W N; Zwelling L A; Plunkett W; Pandita T K; Farquhar D; Newman R A
Biochemical pharmacology of penclomedine (NSC-338720).
Biochemical pharmacology 1995;50(8):1157-64.
1995: Huang P; Robertson L E; Wright S; Plunkett W
High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(9):1005-13.
1995: Robertson L E; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating M J
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(9):1444-9.
1995: Gandhi V; Mineishi S; Huang P; Yang Y; Chubb S; Chapman A J; Nowak B J; Hertel L W; Plunkett W
Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Seminars in oncology 1995;22(4 Suppl 11):61-7.
1995: Plunkett W; Huang P; Xu Y Z; Heinemann V; Grunewald R; Gandhi V
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Seminars in oncology 1995;22(4 Suppl 11):3-10.
1995: Huang P; Plunkett W
Induction of apoptosis by gemcitabine.
Seminars in oncology 1995;22(4 Suppl 11):19-25.
1995: Grégoire V; Ruifrok A C; Price R E; Brock W A; Hittelman W N; Plunkett W K; Ang K K
Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1995;36(1):50-5.
1995: Xie C; Plunkett W
Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.
Cancer research 1995;55(13):2847-52.
1995: Yang L Y; Li L; Keating M J; Plunkett W
Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Molecular pharmacology 1995;47(5):1072-9.
1995: Gandhi V; Mineishi S; Huang P; Chapman A J; Yang Y; Chen F; Nowak B; Chubb S; Hertel L W; Plunkett W
Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells.
Cancer research 1995;55(7):1517-24.
1995: Gandhi V; Estey E; Du M; Nowak B; Keating M J; Plunkett W
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(2):169-78.
1995: Xu Y Z; Huang P; Plunkett W
Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts.
The Journal of biological chemistry 1995;270(2):631-7.
1995: Huang P; Plunkett W
Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event.
Cancer chemotherapy and pharmacology 1995;36(3):181-8.
1994: Grégoire V; Van N T; Stephens L C; Brock W A; Milas L; Plunkett W; Hittelman W N
The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo.
Cancer research 1994;54(23):6201-9.
1994: Gandhi V; Du M; Kantarjian H M; Plunkett W
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(9):1463-8.
1994: Grégoire V; Hunter N; Brock W A; Milas L; Plunkett W; Hittelman W N
Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation.
International journal of radiation oncology, biology, physics 1994;30(2):363-71.
1994: Wright S J; Robertson L E; O'Brien S; Plunkett W; Keating M J
The role of fludarabine in hematological malignancies.
Blood reviews 1994;8(3):125-34.
1994: Ghaddar H M; Plunkett W; Kantarjian H M; Pierce S; Freireich E J; Keating M J; Estey E H
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(8):1269-74.
1994: Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):587-95.
1994: Grégoire V; Hunter N; Milas L; Brock W A; Plunkett W; Hittelman W N
Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
Cancer research 1994;54(2):468-74.
1994: Keating M J; O'Brien S; Plunkett W; Robertson L E; Gandhi V; Estey E; Dimopoulos M; Cabanillas F; Kemena A; Kantarjian H
Fludarabine phosphate: a new active agent in hematologic malignancies.
Seminars in hematology 1994;31(1):28-39.
1994: Keating M J; McLaughlin P; Plunkett W; Robertson L E; O'Brien S; Gandhi V; Gregoire V; Yang L; Cabanillas F
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 2():79-83.
1994: Gandhi V; Robertson L E; Keating M J; Plunkett W
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Cancer chemotherapy and pharmacology 1994;34(1):30-6.
1994: Ellis A L; Nowak B; Plunkett W; Zwelling L A
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Cancer chemotherapy and pharmacology 1994;34(3):249-56.
1994: Gandhi V; Huang P; Plunkett W
Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias.
Leukemia & lymphoma 1994;14 Suppl 2():3-9.
1994: Gandhi V; Estey E; Plunkett W
Modulation of arabinosylcytosine metabolism during leukemia therapy.
Advances in experimental medicine and biology 1994;370():119-24.
1994: Keating M J; Estey E; O'Brien S; Kantarjian H; Robertson L E; Plunkett W
Clinical experience with fludarabine in leukaemia.
Drugs 1994;47 Suppl 6():39-49.
1994: Plunkett W; Gandhi V
Evolution of the arabinosides and the pharmacology of fludarabine.
Drugs 1994;47 Suppl 6():30-8.
1993: Suki S; Kantarjian H; Gandhi V; Estey E; O'Brien S; Beran M; Rios M B; Plunkett W; Keating M
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Cancer 1993;72(7):2155-60.
1993: Plunkett W; Gandhi V; Huang P; Robertson L E; Yang L Y; Gregoire V; Estey E; Keating M J
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Seminars in oncology 1993;20(5 Suppl 7):2-12.
1993: Xu Y Z; Plunkett W
Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells.
The Journal of biological chemistry 1993;268(30):22363-8.
1993: Keating M J; O'Brien S; Kantarjian H; Plunkett W; Estey E; Koller C; Beran M; Freireich E J
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
Blood 1993;81(11):2878-84.
1993: Kemena A; O'Brien S; Kantarjian H; Robertson L; Koller C; Beran M; Estey E; Plunkett W; Lerner S; Keating M J
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Leukemia & lymphoma 1993;10(3):187-93.
1993: Gandhi V; Kemena A; Keating M J; Plunkett W
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
Leukemia & lymphoma 1993;10(1-2):49-56.
1993: Robertson L E; Hall R; Keating M J; Estey E; Kantarjian H M; McLaughlin P; Hagemeister F B; Plunkett W
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.
Leukemia & lymphoma 1993;10(1-2):43-8.
1993: Estey E; Plunkett W; Gandhi V; Rios M B; Kantarjian H; Keating M J
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Leukemia & lymphoma 1993;9(4-5):343-50.
1993: Kantarjian H M; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios M B; Plunkett W; Keating M J
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Blood 1993;81(5):1146-51.
1993: Plunkett W; Gandhi V
Cellular pharmacodynamics of anticancer drugs.
Seminars in oncology 1993;20(1):50-63.
1993: Gandhi V; Estey E; Keating M J; Plunkett W
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):116-24.
1993: Robertson L E; Chubb S; Meyn R E; Story M; Ford R; Hittelman W N; Plunkett W
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
Blood 1993;81(1):143-50.
1993: Estey E H; Plunkett W; Kantarjian H; Rios M B; Keating M J
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Leukemia & lymphoma 1993;10 Suppl():115-21.
1993: Gandhi V; Estey E; Keating M J; Plunkett W
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Leukemia & lymphoma 1993;10 Suppl():109-14.
1993: Robertson L E; Plunkett W
Apoptotic cell death in chronic lymphocytic leukemia.
Leukemia & lymphoma 1993;11 Suppl 2():71-4.
1993: Keating M J; O'Brien S; Robertson L; Huh Y; Kantarjian H; Plunkett W
Chronic lymphocytic leukemia--correlation of response and survival.
Leukemia & lymphoma 1993;11 Suppl 2():167-75.
1992: Huang P; Plunkett W
A quantitative assay for fragmented DNA in apoptotic cells.
Analytical biochemistry 1992;207(1):163-7.
1992: Xu Y Z; Plunkett W
Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine.
Biochemical pharmacology 1992;44(9):1819-27.
1992: Redman J R; Cabanillas F; Velasquez W S; McLaughlin P; Hagemeister F B; Swan F; Rodriguez M A; Plunkett W K; Keating M J
Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):790-4.
1992: Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W
Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):406-13.
1992: Sastry J K; Nehete P N; Khan S; Nowak B J; Plunkett W; Arlinghaus R B; Farquhar D
Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection.
Molecular pharmacology 1992;41(3):441-5.
1992: Gandhi V; Kemena A; Keating M J; Plunkett W
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Cancer research 1992;52(4):897-903.
1992: Heinemann V; Xu Y Z; Chubb S; Sen A; Hertel L W; Grindey G B; Plunkett W
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
Cancer research 1992;52(3):533-9.
1992: Huang P; Farquhar D; Plunkett W
Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases.
The Journal of biological chemistry 1992;267(4):2817-22.
1992: Yang S W; Huang P; Plunkett W; Becker F F; Chan J Y
Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate.
The Journal of biological chemistry 1992;267(4):2345-9.
1992: Keating M J; Estey E; Kantarjian H; Plunkett W; O'Brien S; Koller C; Beran M; Freireich E J
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():78-80.
1992: Kemena A; Gandhi V; Shewach D S; Keating M; Plunkett W
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Cancer chemotherapy and pharmacology 1992;31(3):193-9.
1992: Gandhi V; Plunkett W
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Cancer chemotherapy and pharmacology 1992;31(1):11-7.
1991: Huang P; Chubb S; Hertel L W; Grindey G B; Plunkett W
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Cancer research 1991;51(22):6110-7.
1991: Kemena A; Fernandez M; Bauman J; Keating M; Plunkett W
A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids.
Clinica chimica acta; international journal of clinical chemistry 1991;200(2-3):95-106.
1991: Huang P; Plunkett W
Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.
Molecular pharmacology 1991;39(4):449-55.
1991: Grunewald R; Abbruzzese J L; Tarassoff P; Plunkett W
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
Cancer chemotherapy and pharmacology 1991;27(4):258-62.
1991: Gandhi V; Huang P; Xu Y Z; Heinemann V; Plunkett W
Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity.
Advances in experimental medicine and biology 1991;309A():125-30.
1991: Plunkett W; Saunders P P
Metabolism and action of purine nucleoside analogs.
Pharmacology & therapeutics 1991;49(3):239-68.
1990: Grunewald R; Kantarjian H; Keating M J; Abbruzzese J; Tarassoff P; Plunkett W
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
Cancer research 1990;50(21):6823-6.
1990: Heinemann V; Xu Y Z; Chubb S; Sen A; Hertel L W; Grindey G B; Plunkett W
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Molecular pharmacology 1990;38(4):567-72.
1990: Plunkett W; Huang P; Gandhi V
Metabolism and action of fludarabine phosphate.
Seminars in oncology 1990;17(5 Suppl 8):3-17.
1990: Huang P; Chubb S; Plunkett W
Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.
The Journal of biological chemistry 1990;265(27):16617-25.
1990: Huang P; Farquhar D; Plunkett W
Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases.
The Journal of biological chemistry 1990;265(20):11914-8.
1990: Gandhi V; Plunkett W
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
Cancer research 1990;50(12):3675-80.
1990: Estey E H; Keating M J; McCredie K B; Freireich E J; Plunkett W
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(2):95-9.
1990: Plunkett W; Heinemann V; Estey E; Keating M
Pharmacologically directed design of leukemia therapy.
Haematology and blood transfusion 1990;33():610-3.
1990: Keating M J; Kantarjian H; Estey E; Plunkett W; Trujillo J; McCredie K B
Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia.
Haematology and blood transfusion 1990;33():593-603.
1989: Heinemann V; Plunkett W
Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine.
Biochemical pharmacology 1989;38(22):4115-21.
1989: Gandhi V; Nowak B; Keating M J; Plunkett W
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
Blood 1989;74(6):2070-5.
1989: Gandhi V; Plunkett W
Interaction of arabinosyl nucleotides in K562 human leukemia cells.
Biochemical pharmacology 1989;38(20):3551-8.
1989: Keating M J; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich E J; McCredie K B
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Blood 1989;74(1):19-25.
1989: Heinemann V; Estey E; Keating M J; Plunkett W
Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(5):622-8.
1988: Heinemann V; Hertel L W; Grindey G B; Plunkett W
Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Cancer research 1988;48(14):4024-31.
1988: Gandhi V; Plunkett W
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Cancer research 1988;48(2):329-34.
1988: Heinemann V; Murray D; Walters R; Meyn R E; Plunkett W
Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.
Cancer chemotherapy and pharmacology 1988;22(3):205-10.
1987: Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1987;1(9):638-43.
1987: Estey E; Plunkett W; Dixon D; Keating M; McCredie K; Freireich E J
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1987;1(8):580-3.
1987: Gandhi V; Danhauser L; Plunkett W
Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
Journal of chromatography 1987;413():293-9.
1987: Plunkett W; Grindey G B
Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells.
Nucleic acids symposium series 1987;(18):77-9.
1986: Saunders P P; Tan M T; Spindler C D; Robins R K; Plunkett W
3-Deazaguanosine is metabolized to the triphosphate derivative in Chinese hamster cells deficient in hypoxanthine-guanine phosphoribosyltransferase.
The Journal of biological chemistry 1986;261(14):6416-22.
1985: Plunkett W; Iacoboni S; Estey E; Danhauser L; Liliemark J O; Keating M J
Pharmacologically directed ara-C therapy for refractory leukemia.
Seminars in oncology 1985;12(2 Suppl 3):20-30.

Sign-in to see more